These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35915668)

  • 21. Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery.
    Hong J; Tong Y; He J; Chen X; Shen K
    Ther Adv Med Oncol; 2021; 13():1758835921996673. PubMed ID: 33737963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer.
    Prakash I; Neely NB; Thomas SM; Sammons S; Blitzblau RC; DiLalla GA; Hyslop T; Menendez CS; Plichta JK; Rosenberger LH; Fayanju OM; Hwang ES; Greenup RA
    Cancer Med; 2022 Feb; 11(4):1099-1108. PubMed ID: 34989142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
    Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
    Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.
    Debien V; Adam V; Coart E; Agostinetto E; Goulioti T; Molinelli C; Arahmani A; Zoppoli G; Piccart M
    Future Oncol; 2023 Aug; 19(24):1655-1667. PubMed ID: 37609714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
    Guo X; Zhang J; Gong X; Wang J; Dai H; Jiao D; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; He J; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; Fan Z; Liu Z
    Breast; 2024 Feb; 73():103671. PubMed ID: 38277714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of pathological complete response to neoadjuvant chemotherapy in breast cancer: A single-institution experience.
    Joshi S; Chougle Q; Noronha J; Hawaldar R; Nair N; Vanmali V; Parmar V; Thakkar P; Chitkara G; Shet T; Badwe RA
    Indian J Cancer; 2024 Apr; 61(2):324-331. PubMed ID: 36861728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis.
    Alamoodi M; Wazir U; Mokbel K; Patani N; Varghese J; Mokbel K
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
    Leon-Ferre RA; Hieken TJ; Boughey JC
    Ann Surg Oncol; 2021 Apr; 28(4):2111-2119. PubMed ID: 33486641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
    Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy de-escalation using an
    Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
    Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation.
    Graeser M; Gluz O
    Breast Care (Basel); 2023 Dec; 18(6):455-463. PubMed ID: 38125917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy.
    Tasoulis MK; Muktar S; Smith I; Roche N; MacNeill F
    Eur J Surg Oncol; 2024 Jun; 50(6):108277. PubMed ID: 38522333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
    Weiss A; Campbell J; Ballman KV; Sikov WM; Carey LA; Hwang ES; Poppe MM; Partridge AH; Ollila DW; Golshan M
    Ann Surg Oncol; 2021 Oct; 28(11):5960-5971. PubMed ID: 33821344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    Pfob A; Sidey-Gibbons C; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten M; Golatta M; Heil J
    J Clin Oncol; 2022 Jun; 40(17):1903-1915. PubMed ID: 35108029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
    Wazir U; Mokbel K
    Anticancer Res; 2020 Oct; 40(10):5351-5354. PubMed ID: 32988853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
    Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
    Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
    Garcia-Tejedor A; Fernandez-Gonzalez S; Ortega R; Gil-Gil M; Perez-Montero H; Fernandez-Montolí E; Stradella A; Recalde S; Soler T; Petit A; Bajen MT; Benitez A; Guma A; Campos M; Pla MJ; Martinez E; Laplana M; Pernas S; Perez-Sildekova D; Catala I; Ponce J; Falo C
    Breast Cancer Res Treat; 2021 Feb; 185(3):657-666. PubMed ID: 33068198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
    Cantini L; Trapani D; Guidi L; Boscolo Bielo L; Scafetta R; Koziej M; Vidal L; Saini KS; Curigliano G
    Cancer Treat Rev; 2024 Feb; 123():102669. PubMed ID: 38141462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.
    Kolberg HC; Loevey G; Akpolat-Basci L; Stephanou M; Fasching PA; Untch M; Bulsara M; Vaidya JS; Liedtke C
    Rev Recent Clin Trials; 2017; 12(2):93-100. PubMed ID: 28155607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
    Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
    Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.